Free BPC-157 reconstitution calculator. Enter your vial size (5 mg or 10 mg), BAC water volume, and target dose to get the exact concentration, syringe units to draw, and doses per vial. Includes dosing protocols by injury type, oral vs injectable guidance, and the Wolverine stack (BPC-157 + TB-500) reference. Verify purity before reconstituting with independent lab test data on Peptigrity.
A 5 mg vial of BPC-157 reconstituted with 1 mL of bacteriostatic water gives a concentration of 5.0 mg/mL, or 50 mcg per unit on a U-100 syringe. For a 250 mcg dose, draw the syringe to 5.0 units (0.05 mL). At that dose the vial provides about 20 doses.
Defaults (5 mg vial, 1 mL, 250 mcg) carried over unchanged from this calculator's live defaults (2 September 2026). Arithmetic only, not a recommendation.
Draw the syringe up to
That's one 250 mcg dose. Add 1 mL of water to your 5 mg vial first.
| Step | Dose | Draw on a U-100 | Doses per vial |
|---|---|---|---|
| Standard | 250 mcg | 5 units | 20 |
| Post-surgical | 500 mcg | 10 units | 10 |
Tap any row to load that dose into the calculator above.
BPC-157 dosing in preclinical literature and community protocols clusters around 250-500 mcg per administration, with frequency and route varying by target tissue. All dose ranges below are extrapolated from animal models - no human dose-finding trials have been published.
| Goal | Common Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Tendon / ligament injury | 250 mcg | 1-2× daily | SubQ near injury | 4-8 weeks |
| Muscle tear / strain | 250-500 mcg | 1-2× daily | SubQ near injury | 4-6 weeks |
| Gut healing (IBS, gastritis) | 250-500 mcg | 1-2× daily | Oral or SubQ | 4-8 weeks |
| Post-surgical recovery | 500 mcg | 2× daily | SubQ near site | 2-4 weeks |
| Joint / cartilage | 250 mcg | 1× daily | SubQ near joint | 6-8 weeks |
| General systemic support | 250 mcg | 1× daily | SubQ abdomen | 4-8 weeks |
Oral vs injectable: BPC-157 is one of the few peptides with demonstrated acid stability - the pentadecapeptide structure resists gastric degradation, making oral administration viable for GI targets. For musculoskeletal injuries, injection near the injury site remains preferred.
| Vial | BAC Water | Conc. | 250 mcg Draw | 500 mcg Draw | Doses (250 mcg) |
|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 5 units | 10 units | 20 |
| 5 mg | 2 mL | 2.5 mg/mL | 10 units | 20 units | 20 |
| 10 mg | 2 mL | 5 mg/mL | 5 units | 10 units | 40 |
| 10 mg | 4 mL | 2.5 mg/mL | 10 units | 20 units | 40 |
Common: 5 mg vial + 2 mL BAC water = 2.5 mg/mL. At this concentration, 250 mcg = 10 units and 500 mcg = 20 units - the cleanest measurements. For reconstitution technique, see reconstituting peptides step by step.
| Vial | 250 mcg 1×/day | 250 mcg 2×/day | 500 mcg 1×/day | 500 mcg 2×/day |
|---|---|---|---|---|
| 5 mg | 20 days ✅ | 10 days ✅ | 10 days ✅ | 5 days ✅ |
| 10 mg | 40 days ⚠️ | 20 days ✅ | 20 days ✅ | 10 days ✅ |
A 10 mg vial at 250 mcg once daily lasts 40 days - exceeding the 28-day stability window. Consider partial reconstitution or increased dosing frequency. See how to store peptides.
The most popular BPC-157 combination pairs it with TB-500 for complementary tissue repair. BPC-157 acts locally through VEGF and nitric oxide pathways while TB-500 acts systemically through actin regulation. For blend vial dosing, use the BPC-157 + TB-500 calculator. For the complete protocol, see the Wolverine stack guide.
BPC-157 is one of the most widely sold - and most frequently underdosed - research peptides. Check the CoA for ≥98% HPLC purity and mass spectrometry confirming MW of 1,419.53 Da. Cross-reference against independent lab test results on Peptigrity. For CoA interpretation, see red flags in peptide certificates of analysis.
At 2.5 mg/mL (5 mg vial + 2 mL BAC water): 250 mcg = 10 units. At 5 mg/mL (5 mg vial + 1 mL): 250 mcg = 5 units. The 2.5 mg/mL concentration is commonly cited for clean measurements.
BPC-157 is acid-stable, making oral administration viable for gastrointestinal targets. Oral bioavailability for systemic musculoskeletal effects is lower. Higher oral doses (500 mcg vs 250 mcg injected) are common. For musculoskeletal injuries, subcutaneous injection near the injury site remains preferred.
Inject as close to the injury site as feasible for localised healing. For systemic or GI applications, abdominal injection is standard. BPC-157's short half-life (under 30 minutes) means local concentration at the injection site is higher.
Commonly cited schedules run 4-8 weeks, with some extending to 12 weeks for chronic issues. A 2-4 week break between cycles is commonly cited.
At 250 mcg once daily for 6 weeks (42 days): approximately 2 × 5 mg vials or 1 × 10 mg vial. At twice daily: double those amounts. The calculator shows doses per vial - multiply by your cycle length.
No. BPC-157 acts locally through VEGF and NO pathways. TB-500 acts systemically through actin regulation. They are complementary, not interchangeable. See comparing BPC-157 and TB-500.